TNM staging system may be superior to Lugano and Ann Arbor systems in predicting the overall survival of patients with primary gastrointestinal lymphoma.

PURPOSE To assess the survival predicting value of TNM, Lugano, and Ann Arbor staging systems in patients with primary gastrointestinal lymphoma (PGL). METHODS 101 patients with PGL were reviewed. All of them were staged according to TNM, Lugano, or Ann Arbor staging system. Five-year survival overall survival/OS rate was used as major clinical outcome. The prognostic value of different variables like depth of tumor infiltration (T), lymph node status (N), metastasis (M), sex, age, LDH, ECOG performance status (PS), subtypes, and tumor sites were assessed in relation to clinical outcome. RESULTS The median follow-up time was 46.6 months (range 1.3-158.6). The estimated 5-year OS rate was 74.22%. In gastric lymphoma ,the 5-year OS rate was well correlated with stage in the TNM system (stage I 100.00%, stage II 87.18%, stage III 75.17%, and stage IV 16.67%. p<0.0001), but there were inverse 5-year OS or overlapped survival in the Lugano (81.48% in stage II, 85.71% in stage IIE) and Ann Arbor systems (69.47% in stage IIE, 66.67% in stage IIIE). In aggressive lymphomas, the 5-year OS of TNM stage I, stage II, stage III , and stage IV was 100.00%, 81.34%, 63.52%, and 16.00%, respectively (p=0.0002), but there were overlapped survival curves in Lugano and Ann Arbor systems. The 5-year OS of patients with T1 or T2 was significantly superior compared to patients with T3 or T4 (96.15 vs 67.92%, p=0.0087), and multivariate Cox analysis showed that T (p=0.0181) and M (p=0.0031) were the covariates prognostically significant for OS. CONCLUSION TNM staging system may be superior to Lugano and Ann Arbor system in predicting OS of patients with PGL.

[1]  O. Ayyıldız,et al.  Treatment modalities in primary gastric lymphoma: the effect of rituximab and surgical treatment. A study by the Anatolian Society of Medical Oncology , 2014, Contemporary oncology.

[2]  Minhu Chen,et al.  Clinicopathological characteristics and prognostic factors of primary gastrointestinal lymphoma: a 22-year experience from South China. , 2014, International journal of clinical and experimental pathology.

[3]  Sung-Soo Yoon,et al.  Comparison of Therapeutic Outcomes Between Surgical Resection Followed By R-CHOP and R-CHOP Alone for Localized Primary Intestinal Diffuse Large B-cell Lymphoma , 2014, American journal of clinical oncology.

[4]  Dongbing Ding,et al.  Analysis of clinical characteristics, diagnosis, treatment and prognosis of 46 patients with primary gastrointestinal non-Hodgkin lymphoma. , 2014, Molecular and clinical oncology.

[5]  Z. Zhan,et al.  A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components , 2013, Annals of Hematology.

[6]  N. Iriyama,et al.  Long-term follow-up of localized, primary gastric diffuse large B-cell lymphoma treated with rituximab and CHOP. , 2012, Experimental and therapeutic medicine.

[7]  J. H. Lee,et al.  Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL) , 2011, BMC Cancer.

[8]  R. Xu,et al.  Primary gastric non-Hodgkin's lymphoma in Chinese patients: clinical characteristics and prognostic factors , 2010, BMC Cancer.

[9]  J. Anastasi,et al.  What to do when you suspect gastrointestinal lymphoma: a pathologist's perspective. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[10]  N. Willich,et al.  Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  F. Al-Mulla,et al.  A new cause for CA19.9 elevation: heavy tea consumption , 2003, Gut.

[12]  M. Tsuneyoshi,et al.  Primary gastrointestinal lymphoma in Japan , 2003, Cancer.

[13]  N. Willich,et al.  Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  W. Scheithauer,et al.  Chemotherapy for the treatment of patients with primary high grade gastric B‐cell lymphoma of modified Ann Arbor stages IE and IIE , 2000, Cancer.

[15]  B. Coiffier,et al.  Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.